Zacks Investment Research on MSN
Why Merck's 32% rally isn't enough to change the bearish view
Merck’s MRK stock has risen 32.3% in the past three months. The stock has also been trading above its 50-day and 200-day ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.’s biologics manufacturing facilities, launches Zylidac ...
ImmunityBio (IBRX) stock rises as the company records over 400% YoY groiwth in Q4 net product revenue thanks to its cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback